Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 AUD | +2.88% | +6.84% | +31.23% |
06-17 | Capitol Health Enters Merger Deed with Integral Diagnostics; Shares Hit New 52-Week High | MT |
06-17 | Integral Diagnostics Limited agreed to acquire Capitol Health Limited. | CI |
Valuation
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 496.3 | 759.3 | 1,033 | 694.1 | 764.3 | 568.4 | - | - |
Enterprise Value (EV) 1 | 615.4 | 883.7 | 1,170 | 911.9 | 1,096 | 794.8 | 793.9 | 787.7 |
P/E ratio | 23.8 x | 31.1 x | 33.3 x | 43.9 x | 30.9 x | -12.4 x | 25.1 x | 19.2 x |
Yield | 3.16% | 2.44% | 2.4% | 2.31% | 1.83% | 2.37% | 3.18% | 4.15% |
Capitalization / Revenue | 2.14 x | 2.77 x | 2.94 x | 1.92 x | 1.73 x | 1.2 x | 1.13 x | 1.07 x |
EV / Revenue | 2.65 x | 3.22 x | 3.33 x | 2.53 x | 2.49 x | 1.67 x | 1.58 x | 1.48 x |
EV / EBITDA | 11.6 x | 13.8 x | 12.5 x | 12.2 x | 12.9 x | 8.71 x | 7.73 x | 6.95 x |
EV / FCF | - | 15.9 x | 23.7 x | 97.7 x | 40 x | 32.1 x | 21.6 x | 17.2 x |
FCF Yield | - | 6.3% | 4.21% | 1.02% | 2.5% | 3.12% | 4.62% | 5.8% |
Price to Book | 3.9 x | 3.33 x | 4.05 x | 2 x | 2.05 x | 1.81 x | 1.78 x | 1.73 x |
Nbr of stocks (in thousands) | 157,066 | 194,684 | 198,629 | 229,071 | 233,029 | 233,916 | - | - |
Reference price 2 | 3.160 | 3.900 | 5.200 | 3.030 | 3.280 | 2.430 | 2.430 | 2.430 |
Announcement Date | 19-08-25 | 20-08-24 | 21-08-26 | 22-08-28 | 23-08-27 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 232.4 | 274.1 | 351 | 361 | 440.8 | 474.8 | 503.3 | 533.7 |
EBITDA 1 | 53 | 64.1 | 93.5 | 74.8 | 85.2 | 91.22 | 102.8 | 113.4 |
EBIT 1 | 42 | 49.3 | 58.59 | 38.1 | 43.8 | 46.87 | 55.32 | 64.3 |
Operating Margin | 18.07% | 17.99% | 16.69% | 10.56% | 9.94% | 9.87% | 10.99% | 12.05% |
Earnings before Tax (EBT) 1 | 30.62 | 35.26 | 45.22 | 22.56 | 30.63 | -13.96 | 35.11 | 47 |
Net income 1 | 20.98 | 23 | 31.27 | 14.6 | 25.04 | -49.24 | 23.97 | 30.31 |
Net margin | 9.03% | 8.39% | 8.91% | 4.05% | 5.68% | -10.37% | 4.76% | 5.68% |
EPS 2 | 0.1329 | 0.1253 | 0.1560 | 0.0690 | 0.1060 | -0.1963 | 0.0969 | 0.1264 |
Free Cash Flow 1 | - | 55.7 | 49.31 | 9.33 | 27.42 | 24.76 | 36.71 | 45.71 |
FCF margin | - | 20.32% | 14.05% | 2.58% | 6.22% | 5.22% | 7.29% | 8.57% |
FCF Conversion (EBITDA) | - | 86.9% | 52.74% | 12.47% | 32.19% | 27.15% | 35.72% | 40.32% |
FCF Conversion (Net income) | - | 242.17% | 157.71% | 63.89% | 109.52% | - | 153.14% | 150.8% |
Dividend per Share 2 | 0.1000 | 0.0950 | 0.1250 | 0.0700 | 0.0600 | 0.0576 | 0.0773 | 0.1009 |
Announcement Date | 19-08-25 | 20-08-24 | 21-08-26 | 22-08-28 | 23-08-27 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 131.8 | - | 170.7 | 179.1 | 180.5 | 179.3 | 215.7 | 225.1 | 231.3 | 244.6 | 249.5 | 265.7 |
EBITDA 1 | 29.3 | 34.8 | 52 | 41.5 | 39.5 | 35.3 | 39.8 | 45.4 | 43.2 | 49.6 | 48.8 | 56 |
EBIT 1 | 21.94 | 27.36 | 35 | 23.59 | 22.03 | 16.07 | 19.66 | 24.2 | 21.2 | 25.9 | 25.8 | 32.7 |
Operating Margin | 16.64% | - | 20.5% | 13.17% | 12.2% | 8.96% | 9.11% | 10.75% | 9.17% | 10.59% | 10.34% | 12.31% |
Earnings before Tax (EBT) 1 | - | - | - | 16.39 | - | - | 18.48 | 12.15 | -65.77 | 16.1 | 14.7 | 22.2 |
Net income 1 | 10.9 | 12.1 | 19.9 | 11.37 | 10.2 | 4.403 | 16.14 | 8.903 | -66.8 | 9.25 | 10.6 | 16 |
Net margin | 8.27% | - | 11.66% | 6.35% | 5.65% | 2.46% | 7.48% | 3.96% | -28.88% | 3.78% | 4.25% | 6.02% |
EPS 2 | - | - | - | 0.0562 | - | 0.0187 | - | 0.0375 | -0.2862 | 0.0490 | 0.0450 | 0.0680 |
Dividend per Share 2 | 0.0550 | 0.0400 | 0.0550 | 0.0700 | - | 0.0300 | 0.0250 | 0.0350 | 0.0250 | 0.0350 | 0.0310 | 0.0470 |
Announcement Date | 20-02-19 | 20-08-24 | 21-02-21 | 21-08-26 | 22-02-22 | 22-08-28 | 23-02-16 | 23-08-27 | 24-02-19 | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 119 | 124 | 137 | 218 | 331 | 226 | 225 | 219 |
Net Cash position 1 | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | 2.246 x | 1.941 x | 1.47 x | 2.912 x | 3.888 x | 2.482 x | 2.194 x | 1.934 x |
Free Cash Flow 1 | - | 55.7 | 49.3 | 9.33 | 27.4 | 24.8 | 36.7 | 45.7 |
ROE (net income / shareholders' equity) | 23.2% | 17.6% | 12.9% | 4.85% | 6.95% | 3.49% | 7.79% | 9.79% |
ROA (Net income/ Total Assets) | 10% | 6.97% | 5.04% | 2.03% | 3.09% | 2.74% | 4.86% | 7.22% |
Assets 1 | 209.1 | 330 | 620.9 | 719 | 811 | -1,795 | 493.5 | 419.8 |
Book Value Per Share 2 | 0.8100 | 1.170 | 1.280 | 1.520 | 1.600 | 1.340 | 1.360 | 1.410 |
Cash Flow per Share 2 | 0.2100 | 0.2900 | 0.3500 | 0.1800 | 0.3000 | 0.2400 | 0.3000 | 0.3400 |
Capex 1 | 18.7 | 26.1 | 20.3 | 27.8 | 44 | 34.2 | 36.8 | 39 |
Capex / Sales | 8.03% | 9.52% | 5.77% | 7.69% | 9.98% | 7.2% | 7.32% | 7.3% |
Announcement Date | 19-08-25 | 20-08-24 | 21-08-26 | 22-08-28 | 23-08-27 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.23% | 375M | |
+68.25% | 4.32B | |
+5.67% | 2.74B | |
-2.80% | 2.62B | |
-51.24% | 1.95B | |
-19.04% | 1.67B | |
-22.51% | 1.41B | |
+16.69% | 1.2B | |
-44.81% | 1.12B | |
+16.28% | 975M |
- Stock Market
- Equities
- IDX Stock
- Financials Integral Diagnostics Limited